Narayana Hrudayalaya

    NH
    Pharma
    ₹1,891.30
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹38,412 Cr

    P/E
    44.46
    Day range
    ₹1,869.30 – ₹1,918.80
    52-week range
    ₹1,589.00 – ₹2,092.90
    Volume
    77,210
    Open
    ₹1,898.10
    Prev close
    ₹1,907.60

    Latest results · Q2 FY27(consolidated)Revenue ₹2,844 Cr+73.0%Profit ₹301 Cr+16.5%Margin 10.6%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 56 / 100

    Factor percentiles

    Value39
    Quality47
    Momentum59
    Low volatility80

    Derived metrics

    Earn. yield
    2.2%
    Graham no.
    ₹493.55
    vs Graham
    -73.9%
    ROE ÷ P/B
    2.6%
    12-1 mom.
    -5.1%
    Return / vol
    0.15
    Magic Formula
    #432
    Piotroski
    3/6
    FCF yield
    1.9%
    PEG
    2.69

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Narayana HrudayalayaNH₹38,412 Cr44.467.7319.7%16.0%19.0%1.21+73.0%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 2h ago

    Headlines about Narayana Hrudayalaya from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    42.8
    Price / Book
    7.72
    ROE (FY26)
    19.7%
    ROCE (latest year)
    16%
    Dividend yield
    0.24%

    Moving averages (NSE)

    20-day
    ₹1,810.3
    Price above
    50-day
    ₹1,810.14
    Price above
    200-day
    ₹1,838.81
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +20.4%
    Profit 3Y CAGR
    +9.9%
    Revenue YoY (Sep 2026)
    +73.0%
    Profit YoY (Sep 2026)
    +16.7%
    Operating margin
    19.0%
    Net margin
    10.6%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr1K Cr2K Cr3K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII
    • Others

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-4K Cr-2K Cr0 Cr2K Cr4K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-10%0%10%20%30%40%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2K Cr4K Cr6K Cr8K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x1x2x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY23FY24FY25FY26FY27₹0₹2₹4₹6

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales1,2041,2461,3061,3671,3351,4751,5071,6442,1512,5942,6842,844
    Expenses9259551,0041,0581,0271,1181,1711,2431,7862,0862,2162,293
    Operating Profit279291302309307358337401365508468551
    OPM %23%23%23%23%23%24%22%24%17%20%17%19%
    Other Income1826242318202424-29253552
    Interest252834353741454265918797
    Depreciation6365616570828487122154156163
    Profit before tax209225231232219254232296149288260343
    Tax %10%15%13%14%12%22%15%13%15%22%20%12%
    Net Profit188191202199193197197258127224207301
    EPS in Rs₹9.20₹9.33₹9.85₹9.72₹9.44₹9.65₹9.62₹12.64₹6.20₹10.96₹10.14₹14.73

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days30

    -9 days since Mar 2021

    Inventory Days42

    +10 days since Mar 2021

    Days Payable248

    +27 days since Mar 2021

    Cash Conversion Cycle-176

    -26 days since Mar 2021

    Working Capital Days-19

    +19 days since Mar 2021

    Strengths, risks & growth

    Narayana Hrudayalaya Ltd is engaged in providing economical healthcare services. It has a network of multispecialty and super specialty hospitals spread across multiple locations. [1]

    Strengths

    • Company is expected to give good quarter
    • Company has a good return on equity (ROE) track record: 3 Years ROE 24.5%

    Risks

    • Stock is trading at 7.74 times its book value

    Compounded Sales Growth

    10 Years
    +17%
    5 Years
    +25%
    3 Years
    +20%
    TTM
    +72%

    Compounded Profit Growth

    10 Years
    +42%
    5 Years
    +155%
    3 Years
    +12%
    TTM
    +6%

    Stock Price CAGR

    10 Years
    +19%
    5 Years
    +26%
    3 Years
    +16%
    1 Year
    -6%

    Return on Equity

    10 Years
    +20%
    5 Years
    +26%
    3 Years
    +25%
    Last Year
    +21%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter63.27%63.27%63.27%63.27%0.00 pp
    FII11.10%9.98%9.40%9.01%-0.39 pp
    DII7.91%9.14%9.05%10.68%+1.63 pp
    Government0.00%0.00%0.00%0.00%0.00 pp
    Public17.09%16.98%17.65%16.42%-1.23 pp
    Others0.62%0.62%0.62%0.62%0.00 pp

    Filed with NSE for Sept 2026: promoters 63.27%, public 36.11%

    Analysts & fund holdings

    92%
    92% recommend buy
    12 analysts cover the stock
    Valuation vs Health Care Providers & Services
    P/E44.5 vs 45.2
    Sector P/B6.05
    Beta0.92

    Who holds the shares, quarter by quarter

    Mutual funds 8.70% (+1.31 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters63.7%
    • Foreign institutions9.1%
    • Mutual funds8.7%
    • Insurance1.0%
    • Other domestic institutions1.0%
    • Retail8.2%
    • Others8.3%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Mirae Asset Large & Midcap Fund1.87%1.70%-0.03 pp
    Mirae Asset Midcap Fund1.08%2.12%+0.19 pp
    Parag Parikh Flexi Cap Fund0.89%0.23%-0.04 pp
    Mirae Asset ELSS Tax Saver Fund0.76%1.20%+1.21 pp
    Axis Small Cap Fund0.74%0.98%-0.14 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    29.5%
    Downside volatility
    24.6%
    Worst 5% of days
    2.5%
    Average of that tail
    3.2%
    Max drawdown (1Y)
    21.4%
    Below its peak
    9.1%

    Against the market

    Beta vs Nifty 50
    0.77
    Correlation
    0.36
    Relative strength (3M)
    -0.4%
    ATR (14)
    2.6%

    Return

    Return 1M
    +10.0%
    Return 3M
    +3.4%
    Return 6M
    +1.3%
    Return 1Y
    +4.4%
    vs 200-day average
    +2.9%

    Momentum

    RSI (14)
    59.7
    MACD histogram
    9.98
    Stochastic %K
    77.4
    ADX (14)
    27.9
    +DI / −DI
    28.1 / 18.2
    Money flow index
    78.3

    Participation

    Delivery (20d avg)
    51.9%
    vs its 60-day baseline
    -2.8 pts
    Volume vs 20-day
    -0.7σ
    Close vs day's VWAP
    +0.3%
    52-week position
    60 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    3 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — passed
    Free cash flow
    ₹746 Cr
    FCF yield
    1.9%
    Cash conversion
    2.01
    Accruals ratio
    -0.065
    Net debt
    ₹5,578 Cr
    Net debt / equity
    1.11
    EV / sales
    4.28
    PEG
    2.69
    Capex intensity
    11.1%
    Revenue CAGR
    54.8%
    Profit CAGR
    32.5%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹231 Cr
    0 buys · ₹0
    1 sells · ₹231 Cr
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Shakuntala Shetty
    Promoters · Market Sale
    Sell11,77,000₹231 Cr27 Nov 2025

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹4.50

      Dividend - Rs 4.50 Per Share

      17 Jul 2026
      ex-date
    • dividend
      ₹4.50

      Dividend - Rs 4.50 Per Share

      1 Aug 2025
      ex-date
    • dividend
      ₹4.00

      Dividend - Rs 4 Per Share

      2 Aug 2024
      ex-date
    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      7 Jul 2023
      ex-date
    • dividend
      ₹1.00

      Dividend - Rs 1 Per Share

      22 Aug 2022
      ex-date
    • dividend
      Not available — not reported in this filing

      Interim Dividend - Re 1 Per Share

      11 Mar 2020
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend - Re 1 Per Share

      1 Aug 2019
      ex-date

    Company announcements

    Company Update
    Intimation Of Commencement Of Commercial Operations Of KS-Narayana Hospital, Banashankari, Bengaluru

    Pursuant to Regulation 30 read with Para B of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is the Intimation of commencement ....

    Company Update
    Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements

    Intimation about execution of operation and Management agreement Regaultino 30 read with Schedule III Part A Para B of the SEBI LODR Regualtions 2015

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

    Submission of Scrutinizer report and Voting results of Postal Ballot conducted through remote e-voting

    Company Update
    Intimation Under Regulation 30 Read With Para A Of Part A Of Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

    Intimation under Regulation 30 read with Para A of Part A of Schedule III of the SEBi LODR Regulations, 2015

    Insider Trading / SAST
    Closure of Trading Window

    Intimation for Closure of Trading Window for the quarter ended September 30, 2026.

    Company Update
    Intimation Of Change In Corporate Office Address

    Intimation of Change in Corporate Office Address of the Company.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisement of Postal Ballot Notice.

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    Notice of Postal Ballot

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Schedule of meet of investors to be held on August 20, 2026

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting results and scrutinizers report on the resolutions passed at 26th Annual General meeting held on August 14 2026

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Summary of Proceedings of the 26th Annual General Meeting of the company held on Friday, August 14, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Transcript of the Earnings Call of the company for the quarter ended June 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Group Investor Meeting to be held on August 12, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Schedule of meet of investors to be held on August 07, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Schedule of meet of investors to be held on August 06, 2026

    Filed with BSE (scrip 539551); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 31 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Narayana Hrudayalaya: common questions

    Answered from the figures on this page.

    Narayana Hrudayalaya last traded at ₹1,891.30 (NSE, as of 18 Nov 2026). The last session moved it down 0.85%.

    Narayana Hrudayalaya is valued at about ₹38,412 crore (NSE, as of 18 Nov 2026).

    Narayana Hrudayalaya trades at a price-to-earnings ratio of 44.46 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Narayana Hrudayalaya has traded between ₹1,589.00 and ₹2,092.90 over the past 52 weeks, to 18 Nov 2026. It is currently 60% of the way up that range.

    Narayana Hrudayalaya (NH) is classified under Pharma on this site's screener.